Stocks/NXL/Filings & Earnings

NXL SEC Filings, Earnings & Splits

Key events from SEC filings, earnings beat/miss history, stock split records, and share float data for NXL.

What are NXL's recent SEC filings?

SCHEDULE 13G/A · OtherNov 16, 2026

Alumni Capital LP, along with Alumni Capital GP LLC and Ashkan Mapar, filed an amended Schedule 13G reporting beneficial ownership of 9.99% of Nexalin Technology's common stock, based on warrants and purchase agreements that are subject to a 9.99% ownership cap. The filing states the fund currently owns no shares but has the right to acquire 40,323 shares upon warrant exercise.

View full filing details →
Shares beneficially owned (including right to acquire): $137243, Shares acquirable upon exercise of outstanding warrants: $40323, Shares outstanding as of November 10, 2026: $1.2M
SCHEDULE 13D/A · Material AgreementNov 13, 2026

GreenLight Ventures, LLC filed an amended Schedule 13D reporting beneficial ownership of 133,475 shares (approximately 10.8%) of Nexalin Technology, issued as consideration for the sale of PONM, Inc. under a May 2026 Stock Purchase Agreement, including 87,301 third-tranche shares issued November 10, 2026.

View full filing details →
Total value of Consideration Shares under the Stock Purchase Agreement: $1.3M, Monthly consulting fee under the Collaboration Agreement: $10000, Price per share of the October 20, 2026 issuance triggering anti-dilution adjustment: $2.9782
10-Q · OtherNov 12, 2026

Nexalin Technology filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including revenue, expenses, and balance sheet data. The filing also discloses subsequent ATM program activity through November 12, 2026.

View full filing details →
DEF 14A · OtherNov 6, 2026

Nexalin Technology filed a definitive proxy statement for a special meeting on December 4, 2026, seeking stockholder approval to issue shares to Alumni Capital LP under an Any Market Purchase Agreement in excess of 20% of outstanding shares, as required by Nasdaq Listing Rule 5635(d).

View full filing details →
Outstanding shares of common stock on record date: $1.1M
EFFECT · Shelf RegistrationOct 15, 2026

Nexalin Technology, Inc. had a registration statement declared effective by the SEC, allowing the company to proceed with a securities offering.

View full filing details →
S-1 · Shelf RegistrationOct 8, 2026

Nexalin Technology filed an amendment to its Form S-1 registration statement, including the consent of its independent auditor CBIZ CPAs P.C. for incorporation by reference of its audit report for fiscal year 2025.

View full filing details →
8-K · Material AgreementOct 1, 2026

Nexalin Technology entered into a 10-year exclusive distribution agreement with INOVANEXA MEDICAL TECHNOLOGIES S.A. (Nexalin LATAM) to distribute its Nexalin Sync neurostimulation device across seven South American countries, with an initial 100-device commercialization program and a requirement to establish local manufacturing in Brazil after 30 devices.

View full filing details →
Initial binding purchase order for Nexalin Sync devices: $5, Additional device order required within twelve months of pilot program: $5, Initial commercialization program device count: $100, Device threshold triggering local manufacturing facility requirement: $30
8-K · Delisting NoticeOct 1, 2026

Nexalin Technology received Nasdaq confirmation that it has regained compliance with the $1.00 minimum bid price requirement, but must still demonstrate compliance with the $2,500,000 minimum stockholders' equity requirement by January 4, 2027 to avoid delisting.

View full filing details →
Minimum stockholders' equity requirement for continued Nasdaq listing: $2.5M, Minimum bid price requirement per share: $1
8-K · Delisting NoticeSep 28, 2026

Nexalin Technology received a Nasdaq Hearings Panel notice granting continued listing subject to conditions: demonstrating compliance with the minimum bid price requirement by September 28, 2026, and the stockholders' equity requirement by January 4, 2027.

View full filing details →
minimum stockholders' equity requirement: $2.5M
SCHEDULE 13D · OtherSep 3, 2026

A Schedule 13D was filed regarding Nexalin Technology, Inc., indicating a holder has acquired a greater than 5% beneficial ownership stake with potential activist intent. The filing details are not fully available in the provided text.

View full filing details →

Showing 10 of 11 filings. See all filings with SEPT X-Ray

Has NXL ever done a stock split?

Reverse Split30.0000-for-1.0000 (ratio: 0.033333)
Aug 31, 2026

What is NXL's share float?

Public Float
$9.9M
Shares Outstanding
$22.0M
Free Float %
4486.8%

Get Real-Time NXL Intelligence

SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.

Try SEPT X-Ray Free

More NXL Research

NXL FundamentalsNXL AnalysisSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Filing summaries are extracted automatically from SEC filings and may contain errors. Always verify with official SEC EDGAR filings. Trading involves risk.